TriNetX Partners with Regeneron to Enhance Research through Access to Health Records

TriNetX and Regeneron: A New Frontier in Health Research

In a groundbreaking collaboration, TriNetX® has joined forces with Regeneron Pharmaceuticals, Inc. to harness the power of electronic health records (EHRs) in the pursuit of innovative solutions in life sciences and digital health. This partnership grants Regeneron exclusive access to approximately 300 million de-identified patient records, facilitating a vast array of research and the development of new treatments.

Understanding the Collaboration

This collaboration sits at the intersection of cutting-edge technology and healthcare innovation. By connecting genomic and proteomic data cohorts on a large scale to TriNetX's advanced phenotypic data network, Regeneron aims to significantly increase its genomic and proteomic database tied to electronic health records. This strategic alliance is poised to accelerate drug discovery and development, providing the foundation for AI training algorithms that will drive future digital health solutions.

With TriNetX's expansive global network of healthcare systems, Regeneron will gain secure and licensed access to current and future de-identified health data of around 300 million individuals, including 170 million from the United States alone. This will empower Regeneron to perform more in-depth analyses while adhering to all applicable data privacy laws, such as HIPAA and GDPR.

The Role of Data in Drug Development

Through this collaboration, Regeneron intends to leverage TriNetX's extensive dataset to enhance its ongoing research efforts. TriNetX has established a reputation as a leader in providing real-world data obtained from a growing network of health institutions, boasting over 11,000 healthcare facilities.

The Regeneron Genetics Center® (RGC®) has pioneered cost-effective high-throughput DNA sequencing and proteomic methodologies, creating the largest database of genomic sequencing linked to EHRs. By integrating TriNetX's robust healthcare databases, Regeneron will expand its reference dataset, significantly advancing its therapeutic pipeline and enhancing its capacity for innovative drug development.

Expert Insights from TriNetX and Regeneron

Jeff Margolis, Executive Chairman of TriNetX, expressed enthusiasm about the collaboration, stating, "We are thrilled to partner with Regeneron, especially with the team at the Regeneron Genetics Center. Our focus on applying intelligence-driven information technology will facilitate better human health outcomes through reliable data access."

Moreover, Aris Baras, M.D., Senior Vice President, Director of RGC, commented on the collaboration's importance: "Our mission is to create the world's largest, richest human health database to fuel drug development. TriNetX's proven global research platform is integral to this mission."

Financial Commitment and Future Goals

Regeneron's strategic investment of up to $200 million signifies its commitment to this partnership and highlights the potential impact of their combined efforts in modern medicine. By fusing extensive genomic and health data, the duo aims to push the boundaries of medical science, focusing on the analysis of diseases and crafting digital health solutions that could reshape patient care.

Andrew Deubler, Executive Vice President and Chief Business Officer of RGC, affirmed the partnership's significance, noting, "Our collaborations catalyze innovation, empowering us to accelerate drug development and develop cutting-edge digital health solutions. This agreement reinforces our commitment to expanding our leading network of partners in pursuit of transformative healthcare."

Conclusion

As this collaboration unfolds, the synergy between TriNetX and Regeneron is expected to yield exciting advancements in health research and digital solutions. Their collective efforts promise to not only revolutionize drug discovery but also foster improvements in patient care and healthcare delivery systems globally.

For more information about TriNetX, visit www.trinetx.com and for Regeneron, check www.Regeneron.com. Stay tuned for further developments from this powerful partnership.